{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:15:20Z","timestamp":1794590120936,"version":"4.9.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Survivors of breast cancer present more severe symptoms of genitourinary syndrome of menopause (GSM) than patients without history of breast cancer. Recently, new treatments, such as vaginal laser therapy, have appeared, but evidence of their efficacy remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess the safety and efficacy of carbon dioxide (CO\n                      <jats:sub>2<\/jats:sub>\n                      ) vs sham vaginal laser therapy after 6 months of follow-up in survivors of breast cancer with GSM receiving aromatase inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This prospective double-blind sham-controlled randomized clinical trial with two parallel study groups was performed during October 2020 to March 2022 in a tertiary referral hospital. Survivors of breast cancer using aromatase inhibitors were assessed for eligibility, and eligible patients were randomized into the 2 treatment groups. Follow-up was conducted at 6 months. Data were analyzed in July 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>\n                      All patients from both groups were instructed to use the first-line treatment (FLT) based on nonhormonal moisturizers and vaginal vibrator stimulation. Patients for each group were allocated to 5 monthly sessions of fractional CO\n                      <jats:sub>2<\/jats:sub>\n                      laser therapy (CLT) or sham laser therapy (SLT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was sexual function, evaluated through Female Sexual Function Index (FSFI) score. Other subjective measures of efficacy included a visual analog scale of dyspareunia, vaginal pH, a Vaginal Health Index, quality of life (assessed via Short-Form 12), and body image (assessed with the Spanish Body Image Scale). Objective measures of efficacy included vaginal maturation index, vaginal epithelial elasticity (measured in Pascals) and vaginal epithelial thickness (measured in millimeters). Measures were assessed before and after the intervention. Tolerance (measured on a Likert scale), adverse effects, and estradiol levels were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 211 survivors of breast cancer assessed, 84 women were deemed eligible and 72 women (mean [SD] age, 52.6 [8.3] years) were randomized to CLT (35 participants) or SLT (37 participants) and analyzed. There were no statistically significant differences between groups at baseline. At 6 months, both groups showed improvement in FSFI (mean [SD] score at baseline vs 6 months: CLT, 14.8 [8.8] points vs 20.0 [9.5] points; SLT, 15.6 [7.0] points vs 23.5 [6.5] points), but there was no significant difference between CLT and SLT groups in the improvement of sexual function evaluated through the FSFI test overall (mean [SD] difference, 5.2 [1.5] points vs 7.9 [1.2] points;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.15) or after excluding women who were not sexually active (mean [SD] difference, 2.9 [1.4] points vs 5.5 [1.1] points;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.15). There were also no differences between improvement of the 2 groups at 6 months of follow-up in the other assessed subjective outcomes, including dyspareunia (mean [SD] difference, \u22124.3 [3.4] vs \u22124.5 [2.3];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.73), Vaginal Health Index (mean [SD] difference, 3.3 [4.1] vs 5.0 [4.5];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.17), body image (mean [SD] difference, \u22123.7 [4.5] vs \u22122.7 [4.8];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.35), and quality of life (mean [SD] difference, \u22120.3 [3.6] vs \u22120.7 [3.2];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.39). Similarly, there were no differences in improvements in objective outcomes, including vaginal pH (mean [SD] difference, \u22120.6 [0.9] vs \u22120.8 [1.2];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.29), vaginal maturation index (mean [SD] difference, 10.2 [17.4] vs 14.4 [17.1];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.15), vaginal epithelial thickness (mean [SD] difference, 0.021 [0.014] mm vs 0.013 [0.012] mm;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.30), vaginal epithelial elasticity (mean [SD] difference, \u22121373 [3197] Pascals vs \u22122103 [3771] Pascals;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.64). There were significant improvements in the overall analysis regardless of group in many outcomes. The 2 interventions were well tolerated, but tolerance was significantly lower in the CLT group than the SLT group (mean [SD] Likert scale score, 3.3 [1.3] vs 4.1 [1.0];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.007). No differences were observed in complications or serum estradiol levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this randomized clinical trial, vaginal laser treatment was found to be safe after 6 months of follow-up, but no statistically significant differences in efficacy were observed between CLT and SLT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04619485\">NCT04619485<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.55697","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T12:49:44Z","timestamp":1676033384000},"page":"e2255697","source":"Crossref","is-referenced-by-count":80,"title":["Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause"],"prefix":"10.1001","volume":"6","author":[{"given":"Eduard","family":"Mension","sequence":"first","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Alonso","sequence":"additional","affiliation":[{"name":"Gynecology, Obstetrics and Neonatology Service, Hospital Joan XXIII, Tarragona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f2nia","family":"Angl\u00e8s-Acedo","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ros","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Otero","sequence":"additional","affiliation":[{"name":"Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"CIBER de enfermedades Respiratorias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Villarino","sequence":"additional","affiliation":[{"name":"Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Farr\u00e9","sequence":"additional","affiliation":[{"name":"Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"CIBER de enfermedades Respiratorias, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Saco","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiara","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Castrej\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Ordi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Institute for Global Health, Hospital Cl\u00ednic, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rakislova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Cl\u00ednic of Barcelona, University of Barcelona, Barcelona, Spain"},{"name":"Barcelona Institute for Global Health, Hospital Cl\u00ednic, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tortajada","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Matas","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ribera","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camil","family":"Castelo-Branco","sequence":"additional","affiliation":[{"name":"Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Cl\u00ednic of Barcelona, Barcelona, Spain"},{"name":"Institut d\u00b4Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"1","key":"zoi221582r1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3322\/caac.21203","article-title":"Breast cancer statistics, 2013.","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi221582r2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13697137.2017.1421921","article-title":"Genitourinary syndrome of menopause\u2014prevalence and quality of life in Spanish postmenopausal women: the GENISSE study.","volume":"21","author":"Moral","year":"2018","journal-title":"Climacteric"},{"issue":"2","key":"zoi221582r3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1634\/theoncologist.11-2-96","article-title":"The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors.","volume":"11","author":"Knobf","year":"2006","journal-title":"Oncologist"},{"key":"zoi221582r4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.maturitas.2020.08.010","article-title":"Genitourinary syndrome of menopause: current treatment options in breast cancer survivors\u2014systematic review.","volume":"143","author":"Mension","year":"2021","journal-title":"Maturitas"},{"issue":"5","key":"zoi221582r5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/13697137.2022.2050208","article-title":"Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.","volume":"25","author":"Mension","year":"2022","journal-title":"Climacteric"},{"key":"zoi221582r6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.maturitas.2020.02.009","article-title":"Safety evaluation of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy: a prospective observational study.","volume":"135","author":"Di Donato","year":"2020","journal-title":"Maturitas"},{"issue":"1","key":"zoi221582r7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/GME.0000000000001416","article-title":"A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VELVET Trial.","volume":"27","author":"Paraiso","year":"2020","journal-title":"Menopause"},{"key":"zoi221582r8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.maturitas.2021.06.005","article-title":"Vaginal laser therapy for genitourinary syndrome of menopause\u2014systematic review.","volume":"156","author":"Mension","year":"2022","journal-title":"Maturitas"},{"issue":"1","key":"zoi221582r10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10103-014-1677-2","article-title":"Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment.","volume":"30","author":"Zerbinati","year":"2015","journal-title":"Lasers Med Sci"},{"issue":"2","key":"zoi221582r11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/GME.0000000000001679","article-title":"The ewe as an animal model of vaginal atrophy and vaginal Er:YAG laser application.","volume":"28","author":"Hympanova","year":"2020","journal-title":"Menopause"},{"issue":"14","key":"zoi221582r12","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2021.14892","article-title":"Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial.","volume":"326","author":"Li","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"zoi221582r13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/13697137.2020.1829584","article-title":"CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial.","volume":"24","author":"Salvatore","year":"2021","journal-title":"Climacteric"},{"issue":"1","key":"zoi221582r14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer.","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"zoi221582r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01614576.1976.11074483","article-title":"The PLISSIT model: a proposed conceptual scheme for the behavioural treatment of sexual problems.","volume":"2","author":"Annon","year":"1976","journal-title":"J Sex Educ Ther"},{"issue":"18","key":"zoi221582r16","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1002\/cncr.26739","article-title":"Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors.","volume":"118","author":"Baser","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"zoi221582r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00926230590475206","article-title":"The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores.","volume":"31","author":"Wiegel","year":"2005","journal-title":"J Sex Marital Ther"},{"key":"zoi221582r18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0932","article-title":"Female sexual function in Castilla Y Leon (Spain): normal ranges.","volume":"4","author":"Royo","year":"2014","journal-title":"Gynecol Obstet (Sunnyvale)"},{"issue":"2","key":"zoi221582r19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00520-014-2383-0","article-title":"The Spanish version of the Body Image Scale (S-BIS): psychometric properties in a sample of breast and gynaecological cancer patients.","volume":"23","author":"G\u00f3mez-Campelo","year":"2015","journal-title":"Support Care Cancer"},{"issue":"3","key":"zoi221582r20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"issue":"2","key":"zoi221582r21","first-page":"99","article-title":"Genitourinary syndrome of menopause assessment tools.","volume":"12","author":"Mension","year":"2021","journal-title":"J Midlife Health"},{"issue":"5","key":"zoi221582r22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.ajog.2003.12.015","article-title":"Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis.","volume":"190","author":"Roy","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi221582r23","first-page":"249","article-title":"The maturation value.","volume":"11","author":"Meisels","year":"1967","journal-title":"Acta Cytol"},{"key":"zoi221582r24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcdb.2017.07.020","article-title":"Bidirectional mechanobiology between cells and their local extracellular matrix probed by atomic force microscopy.","volume":"73","author":"Alcaraz","year":"2018","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"zoi221582r27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/aogs.v101.6","article-title":"The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review.","volume":"101","author":"Mortensen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"zoi221582r28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s10103-021-03438-3","article-title":"The efficacy and safety of a combined multipolar radiofrequency with pulsed electromagnetic field technology for the treatment of vaginal laxity: a double-blinded, randomized, sham-controlled trial.","volume":"37","author":"Wattanakrai","year":"2022","journal-title":"Lasers Med Sci"},{"issue":"1","key":"zoi221582r29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10103-021-03305-1","article-title":"The efficacy of erbium-doped yttrium aluminum garnet (Er:YAG) laser in the treatment of decreased sexual sensation: a randomized, placebo-controlled trial.","volume":"37","author":"Sathaworawong","year":"2022","journal-title":"Lasers Med Sci"},{"issue":"7","key":"zoi221582r30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/GME.0000000000001797","article-title":"Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial.","volume":"28","author":"Dutra","year":"2021","journal-title":"Menopause"},{"issue":"4","key":"zoi221582r31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jsxm.2021.01.188","article-title":"A double-blind randomized sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause.","volume":"18","author":"Cruff","year":"2021","journal-title":"J Sex Med"},{"key":"zoi221582r9","author":"Salvatore","year":"2011"},{"key":"zoi221582r25","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Published November 2017. Accessed January 10, 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"zoi221582r26","unstructured":"US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal \u2019rejuvenation\u2019 or vaginal cosmetic procedures: FDA safety communication. News release. August 13, 2018. Accessed January 10, 2023. https:\/\/www.iuga.org\/news\/fda-warns-against-use-of-energy-based-devices-to-perform-vaginal-rejuvenation-or-vaginal-cosmetic-procedures-fda-safety-communication"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801236\/mension_2023_oi_221582_1677779586.1263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T11:05:10Z","timestamp":1678446310000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801236"}},"subtitle":["The LIGHT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55697","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}